585 / 1631
Pharmacokinetic
•
Non-inferior C
trough
with the fixed dose of rituximab SC of 1400 mg
compared with rituximab IV 375 mg/m
2
given every 3 weeks
Efficacy
•
ORR and CR/CRu comparable, indicating the switch to the SC route of administration did not impair
rituximab's anti-lymphoma activity
Safety
•
Rituximab SC safety profile comparable to that of rituximab IV
Summary
and conclusions from SABRINA
Data from additional patients in stage 2 confirm that
rituximab SC 1400 mg has a benefit/risk profile comparable to rituximab IV 375 mg/m
2